TY - JOUR
T1 - Gastrointestinal stromal tumors.
AU - Blanke, Charles D.
AU - Eisenberg, Burton L.
AU - Heinrich, Michael C.
N1 - Funding Information:
Supported in part by a Merit Review Grant from the Department of Veterans Affairs (Michael C. Heinrich) and a grant from the Northwest Health Foundation (Michael C. Heinrich).
PY - 2001/12
Y1 - 2001/12
N2 - Gastrointestinal stromal tumors (GISTs) are mesenchymal gut tumors that differ dramatically from other histologically similar neoplasms, such as leimomyomas, leiomyosarcomas (LMS), and neural tumors. Complete surgical removal remains the best current therapy for GISTs, but even major resections are associated with recurrence in approximately 90% of cases. GISTs are remarkably resistant to irradiation and standard chemotherapy; there is no role for treatment with those modalities. Treatment of advanced GIST patients with STI571, a novel selective tyrosine kinase inhibitor, results in remission rates that approach 60% and overall tumor control rates of 85%. Selected groups of patients, as based on tumor mutational status, have response rates as high as 80%. To date, STI571 therapy remains the only systemic treatment for GISTs to have meaningful clinical activity. Though other molecularly targeted therapies exist in oncology (eg, trastuzumab), STI571 is one of the first that applies a drug specifically designed to inhibit the product of a constitutively-activating mutation that drives pathogenesis of a solid tumor. Its use can serve as a paradigm for designing molecularly targeted therapies for other malignancies.
AB - Gastrointestinal stromal tumors (GISTs) are mesenchymal gut tumors that differ dramatically from other histologically similar neoplasms, such as leimomyomas, leiomyosarcomas (LMS), and neural tumors. Complete surgical removal remains the best current therapy for GISTs, but even major resections are associated with recurrence in approximately 90% of cases. GISTs are remarkably resistant to irradiation and standard chemotherapy; there is no role for treatment with those modalities. Treatment of advanced GIST patients with STI571, a novel selective tyrosine kinase inhibitor, results in remission rates that approach 60% and overall tumor control rates of 85%. Selected groups of patients, as based on tumor mutational status, have response rates as high as 80%. To date, STI571 therapy remains the only systemic treatment for GISTs to have meaningful clinical activity. Though other molecularly targeted therapies exist in oncology (eg, trastuzumab), STI571 is one of the first that applies a drug specifically designed to inhibit the product of a constitutively-activating mutation that drives pathogenesis of a solid tumor. Its use can serve as a paradigm for designing molecularly targeted therapies for other malignancies.
UR - http://www.scopus.com/inward/record.url?scp=0035749620&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035749620&partnerID=8YFLogxK
U2 - 10.1007/s11864-001-0070-0
DO - 10.1007/s11864-001-0070-0
M3 - Review article
C2 - 12057094
AN - SCOPUS:0035749620
SN - 1527-2729
VL - 2
SP - 485
EP - 491
JO - Current treatment options in oncology
JF - Current treatment options in oncology
IS - 6
ER -